About gni ltd - GNIIF
GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. It operates through the following geographical segments: Pharmaceutical and Medical Device Business. The Pharmaceutical segment includes in IceLui, pharmaceutical development, other pharmaceuticals, reagents. The Medical Device segment designated manufacturer and distributor of biomaterials and medical devices, domestic clinical trial administrator services, fabrication of dental prosthetics, dental technology using CAD/CAM, and dental clinic consulting. The company was founded in November 2001 and is headquartered in Tokyo, Japan.
GNIIF At a Glance
GNI Group Ltd.
Nihonbashi-Honcho YS Building, 3/F
Tokyo, Tokyo 103-0023
| Phone | 81-3-6214-3600 | Revenue | 179.41M | |
| Industry | Biotechnology | Net Income | -28,369,075.83 | |
| Sector | Health Technology | 2025 Sales Growth | 15.113% | |
| Fiscal Year-end | 12 / 2026 | Employees | 990 | |
| View SEC Filings |
GNIIF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.50 |
| Price to Book Ratio | 2.668 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -104.551 |
| Enterprise Value to Sales | 4.507 |
| Total Debt to Enterprise Value | 0.175 |
GNIIF Efficiency
| Revenue/Employee | 181,224.592 |
| Income Per Employee | -28,655.632 |
| Receivables Turnover | 3.465 |
| Total Asset Turnover | 0.362 |
GNIIF Liquidity
| Current Ratio | 4.246 |
| Quick Ratio | 3.855 |
| Cash Ratio | 2.451 |
GNIIF Profitability
| Gross Margin | 74.49 |
| Operating Margin | -8.547 |
| Pretax Margin | -17.299 |
| Net Margin | -15.812 |
| Return on Assets | -5.718 |
| Return on Equity | -10.261 |
| Return on Total Capital | -6.133 |
| Return on Invested Capital | -7.181 |
GNIIF Capital Structure
| Total Debt to Total Equity | 44.098 |
| Total Debt to Total Capital | 30.603 |
| Total Debt to Total Assets | 26.483 |
| Long-Term Debt to Equity | 39.422 |
| Long-Term Debt to Total Capital | 27.358 |